Microfragmented Adipose Tissue Is Equivalent to Platelet-Rich Plasma for Knee Osteoarthritis at 12 Months Posttreatment: A Randomized Controlled Trial.

Autor:	Baria M; Department of Physical Medicine and Rehabilitation, The Ohio State University, Columbus, Ohio, USA., Barker T; Sports Medicine Research Institute, The Ohio State University, Columbus, Ohio, USA., Durgam S; College of Veterinary Sciences, The Ohio State University, Columbus, Ohio, USA., Pedroza A; Sports Medicine Research Institute, The Ohio State University, Columbus, Ohio, USA., Flanigan D; Department of Orthopedic Surgery, The Ohio State University, Columbus, Ohio, USA., Jia L; Sports Medicine Research Institute, The Ohio State University, Columbus, Ohio, USA., Kaeding C; Department of Orthopedic Surgery, The Ohio State University, Columbus, Ohio, USA., Magnussen R; Department of Orthopedic Surgery, The Ohio State University, Columbus, Ohio, USA.
Jazyk:	angličtina
Zdroj:	Orthopaedic journal of sports medicine [Orthop J Sports Med] 2024 Mar 18; Vol. 12 (3), pp. 23259671241233916. Date of Electronic Publication: 2024 Mar 18 (Print Publication: 2024).
DOI:	10.1177/23259671241233916
Abstrakt:	Background: Platelet-rich plasma (PRP) is an effective treatment for knee osteoarthritis (OA). Microfragmented adipose tissue (MFAT) is another orthobiologic that holds promise, but data supporting its use are limited. Previous studies showed that MFAT created using the Lipogems device was equivalent to PRP created via noncommercial laboratory-based processes. Purpose: To perform a comparison of commercially available MFAT and PRP systems for treatment of knee OA. Study Design: Randomized controlled trial; Level of evidence, 2. Methods: A total of 71 patients with symptomatic knee OA (Kellgren-Lawrence grades 1-4) were randomized to receive a single injection of either leukocyte-rich PRP (Angel; Arthrex) or MFAT (Lipogems) under ultrasound guidance. Patient-reported outcomes (Knee injury and Osteoarthritis Outcome Score [KOOS], visual analog scale for pain with activities of daily living [VAS pain], and Tegner activity level) were recorded at baseline and at 1, 3, 6, and 12 months after injection. The primary outcome was the KOOS-Pain subscale score at 12 months after injection. Results: Overall, 49 patients completed their 12-month follow-up (PRP group, n = 23; MFAT group, n = 26). All demographic features were similar between groups, except that more men were randomized to the PRP group and more women to the MFAT group. At 12 months posttreatment, KOOS-Pain scores improved in both groups, with no significant group difference (PRP, 78 ± 17.9 vs MFAT, 77.8 ± 19.3; P = .69). Similarly, other KOOS subscales, VAS pain scores, and Tegner scores improved at 12 months, with no differences between treatment groups. Conclusion: Both PRP and MFAT injections for knee OA resulted in improved patient-reported outcomes at 12 months posttreatment, with no differences found between treatments. Registration: NCT04351087 (ClinicalTrials.gov identifier). Competing Interests: One or more of the authors has declared the following potential conflict of interest or source of funding: Research support was received from the Lisa Dean Moseley Foundation. M.B. has received education payments from CDC Medical, consulting fees from Arthrex, and nonconsulting fees from Arthrex and Terumo BCT. D.F. has received consulting fees from DePuy Synthes Products, Linvatec, Medical Device Business Services, Smith & Nephew, Vericel, Bioventus, Zimmer Biomet Holdings, and Ceterix Orthopaedics; nonconsulting fees from Karl Storz Endoscopy, Smith & Nephew, Linvatec, and Pacira Pharmaceuticals; and honoraria from Vericel. C.K. has received education payments from CDC Medical, consulting fees from Arthrex and Bioventus, nonconsulting fees from Arthrex and Smith & Nephew, and honoraria from NovoPedics. R.M. has received a grant from DJO and education payments from CDC Medical. AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto. Ethical approval for this study was obtained from The Ohio State University (ref No. 2019H0448). (© The Author(s) 2024.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu